Albendazole
Cysticercosis
R-Evolution Worldwide S.r.l. Impresa SocialeSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Cysticercosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Praziquantel R-Evolution Worldwide S.r.l. Impresa Sociale | Phase 4 | BBB |
PBR28 National Institute of Mental Health (NIMH) | Phase 1 | CC |
[F-18]FBR National Institute of Mental Health (NIMH) | Phase 1 | CC |
DEXAMETHASONE Johns Hopkins University | N/A | D |
PHENYTOIN Johns Hopkins University | N/A | D |
Same molecule, other indications
Albendazole is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →